期刊
LABORATORY INVESTIGATION
卷 91, 期 9, 页码 1375-1382出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/labinvest.2011.78
关键词
core protein; hepatic stellate cells; hepatitis C virus; liver fibrosis; toll-like receptor 2
资金
- BONFOR [O-107.0097]
- Deutsche Krebshilfe [107865]
- Deutsche Forschungsgemeinschaft [SFB TR57 TP12]
Hepatic stellate cells (HSCs) represent the main fibrogenic cell type accumulating extracellular matrix in the liver. Recent data suggest that hepatitis C virus (HCV) core protein may directly activate HSCs. Therefore, we examined the influence of recombinant HCV core protein on human HSCs. Primary human HSCs and the human HSC line LX-2 were stimulated with recombinant HCV proteins core and envelope 2 protein. Expression of procollagen type I alpha-1, alpha-smooth muscle actin, cysteine-and glycine-rich protein 2, glial fibrillary acidic protein, tissue growth factor beta 1, matrix metalloproteinases 2 (MMP2) and 13, tissue inhibitor of metalloproteinases 1 and 2 was investigated by real-time PCR. Intracellular signaling pathways of ERK1/2, p38 and, jun-amino-terminal kinase (JNK) were analyzed by western blot analysis. Recombinant HCV core protein induced upregulation of procollagen type I alpha-1, alpha-smooth muscle actin, MMP 2 and 13, tissue inhibitor of metalloproteinases 1 and 2, tissue growth factor beta 1, cysteine-and glycine-rich protein 2, and glial fibrillary acidic protein mRNA expression, whereas HCV envelope 2 protein did not exert any significant effect. Blocking of toll-like receptor 2 (TLR2) with a neutralizing antibody prevented mRNA upregulation by HCV core protein confirming that the TLR2 pathway was involved. Furthermore, western blot analysis revealed HCV-induced phosphorylation of the TLR2-dependent signaling molecules ERK1/2, p38 and JNK mitogen-activated kinases. Our in vitro results demonstrate a direct effect of HCV core protein on activation of HSCs toward a profibrogenic state, which is mediated via the TLR2 pathway. Manipulating the TLR2 pathway may thus provide a new approach for antifibrotic therapies in HCV infection. Laboratory Investigation (2011) 91, 1375-1382; doi: 10.1038/labinvest. 2011.78; published online 2 May 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据